Company Overview
AdaptHealth Corp. operates within the healthcare sector specifically as a medical device company, focusing on the distribution of home medical equipment, medical supplies, and associated services throughout the United States. The organization segments its operations into Sleep Health, Respiratory Health, Diabetes Health, and Wellness at Home, offering sleep therapy equipment and related solutions to patients in residential settings. This entity maintains a significant operational footprint with an employee count of 10,900, reflecting a substantial workforce dedicated to managing complex supply chains and service delivery networks. The company currently holds a market capitalization of $1.56B and reports annual revenue of $3.24B, figures that indicate it is a major player capable of influencing market dynamics within the home medical equipment distribution landscape. These valuation and revenue metrics suggest the company possesses a large-scale infrastructure necessary to support its diverse portfolio of health services and equipment distribution.
Financial Health
The company reported revenue of $3.24B for the trailing twelve months, yet recorded a net income of $-70,794,000 and an EBITDA of $586.49M, revealing a significant gap where operating profitability is substantially higher than reported net income. This discrepancy highlights a heavy burden from non-operating expenses, interest costs, or other charges that eride earnings after the calculation of operating cash flows. Despite the negative net income, the business generates a free cash flow of $246.52M, which provides the financial flexibility to service debt obligations, invest in operational improvements, or return capital to stakeholders without relying on external financing. The gross margin stands at 20.9%, indicating the percentage of revenue remaining after direct costs of goods sold, while the operating margin of 6.2% reflects the efficiency of core business operations before interest and taxes. The profit margin is negative at -2.2%, signaling that overall profitability has been compromised by high interest expenses or other financial costs. In terms of balance sheet strength, the company holds $106.24M in cash against $1.90B in total debt, resulting in a debt-to-equity ratio of 124.67, which indicates a highly leveraged position where debt obligations significantly exceed equity capitalization. The current ratio is 1.02, suggesting that the company's current assets barely cover its current liabilities, implying tight short-term liquidity conditions with limited buffer against unexpected cash flow interruptions. Return on equity is -4.3% and return on assets is 2.9%, metrics that reveal management is currently generating returns that are insufficient to cover the cost of equity capital and show limited efficiency in utilizing total assets to generate net profit.
Valuation Assessment
The valuation metrics show a trailing P/E ratio of N/A and a forward P/E of 9.23, implying that the market prices the stock based on anticipated future earnings growth rather than current profitability. The absence of a trailing P/E confirms that the company is not currently profitable on a historical basis, making forward-looking metrics the primary tool for assessing value. The price-to-book ratio is 1.00, which indicates that the market values the company exactly at its book value, suggesting no premium or discount relative to the net asset value of the firm. Additionally, the price-to-sales ratio is 0.48 and the EV/EBITDA is 5.74, alternative metrics that suggest the stock trades at a fraction of its sales revenue and offers a low multiple relative to its earnings before interest, taxes, depreciation, and amortization. Regarding price movement, the 52-week high is $11.69 and the 52-week low is $7.11, placing the current trading environment within a range that has seen significant volatility over the last year. The beta value is 1.72, meaning the stock's price volatility is significantly higher than the broader market, reacting with approximately 72% greater intensity to market-wide movements.
Growth & Income
Revenue growth year over year stands at -1.2%, while earnings growth year over year is N/A due to the lack of positive net income in the trailing period. The negative revenue growth indicates a slight contraction in top-line sales, whereas the absence of earnings growth further underscores the challenges in improving bottom-line performance during this period. As the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, meaning the firm retains all earnings and cash flow to reinvest into operations, pay down debt, or acquire other assets rather than distributing income to shareholders. This retention strategy is typical for leveraged companies seeking to strengthen their balance sheet or fund expansion in a competitive market. Overall, the growth and income profile reflects a company currently prioritizing capital preservation and operational restructuring over income distribution or top-line expansion.